Correction to: Whole-genome sequencing identifies responders to Pembrolizumab in relapse/refractory natural-killer/T cell lymphoma (Leukemia, (2020), 34, 12, (3413-3419), 10.1038/s41375-020-1000-0)

Jing Quan Lim; Dachuan Huang; Tiffany Tang; Daryl Tan; Yurike Laurensia; Rou Jun Peng; Esther Kam Yin Wong; Daryl Ming Zhe Cheah; Burton Kuan Hui Chia; Jabed Iqbal; Nicholas Francis Grigoropoulos; Maarja Liisa Nairismägi; Cedric Chuan Young Ng; Vikneswari Rajasegaran; Huangming Hong; Seok Jin Kim; Junhun Cho; Eric Tse; Benjamin Mow; Qi Chun Cai; Li Mei Poon; Qing qing Cai; Jing Tan; Jason Yongsheng Chan; Johnathan Xiande Lim; Yeow Tee Goh; Colin Phipps; Olaf Rötzschke; Chee Leong Cheng; Jeslin Chian Hung Ha; Lay Poh Khoo; Yvonne Su Ming Loh; Rex Au-Yeung; Thomas Sau Yan Chan; Yok Lam Kwong; William Hwang; Won Seog Kim; Jin Xin Bei; Tongyu Lin; Choon Kiat Ong; Soon Thye Lim

doi:10.1038/s41375-021-01195-4

Correction to: Whole-genome sequencing identifies responders to Pembrolizumab in relapse/refractory natural-killer/T cell lymphoma (Leukemia, (2020), 34, 12, (3413-3419), 10.1038/s41375-020-1000-0)

Jing Quan Lim, Dachuan Huang, Tiffany Tang, Daryl Tan, Yurike Laurensia, Rou Jun Peng, Esther Kam Yin Wong, Daryl Ming Zhe Cheah, Burton Kuan Hui Chia, Jabed Iqbal, Nicholas Francis Grigoropoulos, Maarja Liisa Nairismägi, Cedric Chuan Young Ng, Vikneswari Rajasegaran, Huangming Hong, Seok Jin Kim, Junhun Cho, Eric Tse, Benjamin Mow, Qi Chun CaiLi Mei Poon, Qing qing Cai, Jing Tan, Jason Yongsheng Chan, Johnathan Xiande Lim, Yeow Tee Goh, Colin Phipps, Olaf Rötzschke, Chee Leong Cheng, Jeslin Chian Hung Ha, Lay Poh Khoo, Yvonne Su Ming Loh, Rex Au-Yeung, Thomas Sau Yan Chan, Yok Lam Kwong, William Hwang, Won Seog Kim, Jin Xin Bei, Tongyu Lin, Choon Kiat Ong, Soon Thye Lim

Research output: Contribution to journal › Comment/debate

Abstract

The authors did not declare a relevant conflict of interest thus wish to publish a correction to add this: Compliance with ethical standards Conflict of interest JQL, CKO and STL are co-inventors of the patent filed under International Application No. PCT/SG2018/050509 by Singapore Health Services Pte Ltd which is related to this work. At the time of writing, the co-inventors did not receive honoraria for this work. The patent has been licensed to Lucence (did not take part in this study).

Original language	English
Pages (from-to)	1225
Number of pages	1
Journal	Leukemia
Volume	35
Issue number	4
DOIs	https://doi.org/10.1038/s41375-021-01195-4
State	Published - Apr 2021
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/s41375-021-01195-4

Cite this

Lim, J. Q., Huang, D., Tang, T., Tan, D., Laurensia, Y., Peng, R. J., Wong, E. K. Y., Cheah, D. M. Z., Chia, B. K. H., Iqbal, J., Grigoropoulos, N. F., Nairismägi, M. L., Ng, C. C. Y., Rajasegaran, V., Hong, H., Kim, S. J., Cho, J., Tse, E., Mow, B., ... Lim, S. T. (2021). Correction to: Whole-genome sequencing identifies responders to Pembrolizumab in relapse/refractory natural-killer/T cell lymphoma (Leukemia, (2020), 34, 12, (3413-3419), 10.1038/s41375-020-1000-0). Leukemia, 35(4), 1225. https://doi.org/10.1038/s41375-021-01195-4

@article{370f9e7efa524e81bb427b1e1b690342,

title = "Correction to: Whole-genome sequencing identifies responders to Pembrolizumab in relapse/refractory natural-killer/T cell lymphoma (Leukemia, (2020), 34, 12, (3413-3419), 10.1038/s41375-020-1000-0)",

abstract = "The authors did not declare a relevant conflict of interest thus wish to publish a correction to add this: Compliance with ethical standards Conflict of interest JQL, CKO and STL are co-inventors of the patent filed under International Application No. PCT/SG2018/050509 by Singapore Health Services Pte Ltd which is related to this work. At the time of writing, the co-inventors did not receive honoraria for this work. The patent has been licensed to Lucence (did not take part in this study).",

author = "Lim, \{Jing Quan\} and Dachuan Huang and Tiffany Tang and Daryl Tan and Yurike Laurensia and Peng, \{Rou Jun\} and Wong, \{Esther Kam Yin\} and Cheah, \{Daryl Ming Zhe\} and Chia, \{Burton Kuan Hui\} and Jabed Iqbal and Grigoropoulos, \{Nicholas Francis\} and Nairism{\"a}gi, \{Maarja Liisa\} and Ng, \{Cedric Chuan Young\} and Vikneswari Rajasegaran and Huangming Hong and Kim, \{Seok Jin\} and Junhun Cho and Eric Tse and Benjamin Mow and Cai, \{Qi Chun\} and Poon, \{Li Mei\} and Cai, \{Qing qing\} and Jing Tan and Chan, \{Jason Yongsheng\} and Lim, \{Johnathan Xiande\} and Goh, \{Yeow Tee\} and Colin Phipps and Olaf R{\"o}tzschke and Cheng, \{Chee Leong\} and Ha, \{Jeslin Chian Hung\} and Khoo, \{Lay Poh\} and Loh, \{Yvonne Su Ming\} and Rex Au-Yeung and Chan, \{Thomas Sau Yan\} and Kwong, \{Yok Lam\} and William Hwang and Kim, \{Won Seog\} and Bei, \{Jin Xin\} and Tongyu Lin and Ong, \{Choon Kiat\} and Lim, \{Soon Thye\}",

note = "Publisher Copyright: {\textcopyright} 2021, The Author(s), under exclusive licence to Springer Nature Limited.",

year = "2021",

month = apr,

doi = "10.1038/s41375-021-01195-4",

language = "English",

volume = "35",

pages = "1225",

journal = "Leukemia",

issn = "0887-6924",

publisher = "Springer Nature",

number = "4",

}

Lim, JQ, Huang, D, Tang, T, Tan, D, Laurensia, Y, Peng, RJ, Wong, EKY, Cheah, DMZ, Chia, BKH, Iqbal, J, Grigoropoulos, NF, Nairismägi, ML, Ng, CCY, Rajasegaran, V, Hong, H, Kim, SJ, Cho, J, Tse, E, Mow, B, Cai, QC, Poon, LM, Cai, QQ, Tan, J, Chan, JY, Lim, JX, Goh, YT, Phipps, C, Rötzschke, O, Cheng, CL, Ha, JCH, Khoo, LP, Loh, YSM, Au-Yeung, R, Chan, TSY, Kwong, YL, Hwang, W, Kim, WS, Bei, JX, Lin, T, Ong, CK & Lim, ST 2021, 'Correction to: Whole-genome sequencing identifies responders to Pembrolizumab in relapse/refractory natural-killer/T cell lymphoma (Leukemia, (2020), 34, 12, (3413-3419), 10.1038/s41375-020-1000-0)', Leukemia, vol. 35, no. 4, pp. 1225. https://doi.org/10.1038/s41375-021-01195-4

TY - JOUR

T1 - Correction to

T2 - Whole-genome sequencing identifies responders to Pembrolizumab in relapse/refractory natural-killer/T cell lymphoma (Leukemia, (2020), 34, 12, (3413-3419), 10.1038/s41375-020-1000-0)

AU - Lim, Jing Quan

AU - Huang, Dachuan

AU - Tang, Tiffany

AU - Tan, Daryl

AU - Laurensia, Yurike

AU - Peng, Rou Jun

AU - Wong, Esther Kam Yin

AU - Cheah, Daryl Ming Zhe

AU - Chia, Burton Kuan Hui

AU - Iqbal, Jabed

AU - Grigoropoulos, Nicholas Francis

AU - Nairismägi, Maarja Liisa

AU - Ng, Cedric Chuan Young

AU - Rajasegaran, Vikneswari

AU - Hong, Huangming

AU - Kim, Seok Jin

AU - Cho, Junhun

AU - Tse, Eric

AU - Mow, Benjamin

AU - Cai, Qi Chun

AU - Poon, Li Mei

AU - Cai, Qing qing

AU - Tan, Jing

AU - Chan, Jason Yongsheng

AU - Lim, Johnathan Xiande

AU - Goh, Yeow Tee

AU - Phipps, Colin

AU - Rötzschke, Olaf

AU - Cheng, Chee Leong

AU - Ha, Jeslin Chian Hung

AU - Khoo, Lay Poh

AU - Loh, Yvonne Su Ming

AU - Au-Yeung, Rex

AU - Chan, Thomas Sau Yan

AU - Kwong, Yok Lam

AU - Hwang, William

AU - Kim, Won Seog

AU - Bei, Jin Xin

AU - Lin, Tongyu

AU - Ong, Choon Kiat

AU - Lim, Soon Thye

PY - 2021/4

Y1 - 2021/4

N2 - The authors did not declare a relevant conflict of interest thus wish to publish a correction to add this: Compliance with ethical standards Conflict of interest JQL, CKO and STL are co-inventors of the patent filed under International Application No. PCT/SG2018/050509 by Singapore Health Services Pte Ltd which is related to this work. At the time of writing, the co-inventors did not receive honoraria for this work. The patent has been licensed to Lucence (did not take part in this study).

AB - The authors did not declare a relevant conflict of interest thus wish to publish a correction to add this: Compliance with ethical standards Conflict of interest JQL, CKO and STL are co-inventors of the patent filed under International Application No. PCT/SG2018/050509 by Singapore Health Services Pte Ltd which is related to this work. At the time of writing, the co-inventors did not receive honoraria for this work. The patent has been licensed to Lucence (did not take part in this study).

UR - https://www.scopus.com/pages/publications/85102191557

U2 - 10.1038/s41375-021-01195-4

DO - 10.1038/s41375-021-01195-4

M3 - Comment/debate

C2 - 33686199

AN - SCOPUS:85102191557

SN - 0887-6924

VL - 35

SP - 1225

JO - Leukemia

JF - Leukemia

IS - 4

ER -

Correction to: Whole-genome sequencing identifies responders to Pembrolizumab in relapse/refractory natural-killer/T cell lymphoma (Leukemia, (2020), 34, 12, (3413-3419), 10.1038/s41375-020-1000-0)

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this